AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal ...

AbbVie Inc. ABBV shares are edging higher Friday morning following Thursday’s announcement of positive Phase 3 trial results ...

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough ...

AbbVie's dividend is a very appealing factor.

AbbVie stock closed at USD 261.77 on the NYSE on September 14, 2026, marking a 1.81 percent gain versus its prior close and ...

AbbVie (NYSE:ABBV | ABBV Price Prediction) at $224.95 sits at the center of a sharp bull-bear debate. The pharma giant has climbed 53.59% since the start of 2024 off its 2024 lows, but a balance sheet ...

AbbVie remains a 'Buy', supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. The recent $11B Apogee Therapeutics acquisition enhances ABBV's pipeline in ...

AbbVie stock has delivered a strong 152.2% return over the past 5 years, yet the valuation signals are split, with a ...

At the close on September 10, 2026, AbbVie stock finished at USD 254.99 on the New York Stock Exchange, up 1.6% from the ...